Search results for "Bowel disease"

showing 10 items of 449 documents

Gene transfer approaches for the treatment of inflammatory bowel disease.

2003

The pathogenesis of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease, involves a complex interplay between certain genetic, environmental and immunological factors. Considerable research progress in the last decade defined key inflammatory pathways in the inflamed gut and identified new potential therapeutic targets. Since the current medical treatment with corticosteroids and anti-inflammatory drugs is often associated with undesired side effects and cannot completely cure IBD, these current advances in our understanding of intestinal pathology may now allow the development of new biologic treatment strategies including gene therapy. In this review,…

Genetic enhancementGenetic VectorsGene ExpressionGene transferDiseaseInflammatory bowel diseaseAdenoviridaePathogenesisCrohn DiseaseIntestinal inflammationGeneticsMedicineAnimalsHumansMolecular BiologyMedical treatmentbusiness.industryBacterial InfectionsGenetic Therapymedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisIntestinesDisease Models AnimalImmunologyMolecular MedicineCytokinesColitis UlcerativeImmunotherapybusinessStem Cell TransplantationGene therapy
researchProduct

Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.

2017

Vedolizumab (VDZ) is a new biological agent which was recently approved for the treatment of inflammatory bowel disease (IBD)1 following the good clinical responses reported by clinical trials for both Crohn's disease2 and ulcerative colitis.3 However, the effects of VDZ on extraintestinal manifestations were not reported in these trials, and the ‘real life’ experience is still limited. On these premises, we read with interest the recent work by Varkas et al 4 reporting a series of five patients with IBD who were treated with VDZ and promptly developed new onset or exacerbation of spondyloarthritis (SpA), irrespective of the response to treatment on intestinal symptoms. Although the hypothe…

Genetics and Molecular Biology (all)medicine.medical_specialtyExacerbationT CellImmunologyPremisesAntibodies Monoclonal HumanizedBiochemistryInflammatory bowel diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyNew onsetVedolizumab03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineSpondylarthritismedicineImmunology and AllergyHumansIn patientSacroiliitis030203 arthritis & rheumatologyBiochemistry Genetics and Molecular Biology (all)business.industrymedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesRheumatologyTreatmentClinical trial030211 gastroenterology & hepatologySpondyloarthritis; T Cells; Treatment; Rheumatology; Immunology and Allergy; Immunology; Biochemistry Genetics and Molecular Biology (all)Spondyloarthritibusinessmedicine.drugAnnals of the rheumatic diseases
researchProduct

Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing…

2016

Background Ulcerative colitis (UC), a complex polygenic disorder, is one of the main subphenotypes of inflammatory bowel disease. A comprehensive dissection of the genetic etiology of UC needs to assess the contribution of rare genetic variants including copy number variations (CNVs) to disease risk. In this study, we performed a multi-step genome-wide case-control analysis to interrogate the presence of disease-relevant rare copy number variants. Methods One thousand one hundred twenty-one German UC patients and 1770 healthy controls were initially screened for rare deletions and duplications employing SNP-array data. Quantitative PCR and high density custom array-CGH were used for validat…

GeneticsHepatologyIn silicoBiologymedicine.diseaseGenomeInflammatory bowel diseasePrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisGene duplicationGenotypemedicine030211 gastroenterology & hepatologyCopy-number variationGeneJournal of Hepatology
researchProduct

Telemedicina en el manejo de pacientes con enfermedad inflamatoria intestinal

2017

Inflammatory bowel disease (IBD) is a chronic and relapsing disorder with significant medical, social and financial impacts. IBD patients require continuous follow-up, and healthcare resource use in this context increases over time. In the last decade, telemedicine has influenced the treatment of chronic diseases like IBD via the application of information and communication technologies to provide healthcare services remotely. Telemedicine and its various applications (telemanagement, teleconsulting and tele-education) enable closer follow-up and provide education resources that promote patient empowerment, encouraging treatment optimisation over the entire course of the disease. We describ…

Gerontologymedicine.medical_specialtyTelemedicineHepatologybusiness.industryPatient EmpowermentGastroenterologyContext (language use)Diseasemedicine.diseaseHealth outcomesInflammatory bowel diseasedigestive system diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisHealth caremedicineResource use030211 gastroenterology & hepatologybusinessIntensive care medicineGastroenterología y Hepatología
researchProduct

Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines…

2011

Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroidd…

Guidelines.Biologics.Inflammatory bowel disease.
researchProduct

The many roads to inflammatory bowel diseases.

2006

Two independent studies by Rakoff-Nahoum et al. (2006) and Uhlig et al. (2006) in this issue of Immunity have illuminated a unique pathogenic role of innate immunity via Toll-like receptor and interleukin-23 signaling, respectively, in intestinal inflammation. These data define new roads to gut inflammation and future avenues for therapy.

Gut inflammationInnate immune systemInterleukinsImmunologyToll-Like ReceptorsInflammatory Bowel DiseasesBiologyInflammatory Bowel DiseasesInterleukin-12Interleukin-23Immunity InnateInfectious DiseasesImmunityIntestinal inflammationImmunologyImmunology and AllergyAnimalsSignal TransductionImmunity
researchProduct

Zur Immunpathogenese der chronisch entz�ndlichen Darmerkrankungen

2000

Die chronisch entzundlichen Darmerkrankungen (CED: Morbus Crohn, Colitis ulcerosa) sind durch schubartig verlaufende destruierende Entzundungsreaktionen der Darmschleimhaut gekennzeichnet. In den letzten Jahren konnte gezeigt werden, das bei diesen Erkrankungen eine pathologische Aktivierung des intestinalen Immunsystems durch mucosale Antigene auftritt. In der chronischen Phase der Erkankungen sowie bei der Entwicklung postoperativer Rezidive sind Anderungen in der Zellmigration sowie der Cytokinproduktion intestinaler Zellen wahrscheinlich von entscheidender Bedeutung. Basierend auf diesen neuen pathogenetischen Erkenntnissen werden zur Zeit innovative klinische Behandlungsstrategien gete…

Gynecologymedicine.medical_specialtyTransplant surgeryIntestinal mucosabusiness.industryCrohn diseasemedicineInflammatory Bowel DiseasesSurgerybusinessGenetic therapyDer Chirurg
researchProduct

Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure

2016

Hepatologybiologybusiness.industryImmunoglobulin Fab FragmentsGastroenterologyInflammatory Bowel DiseasesToxicology03 medical and health sciences0302 clinical medicineAntibodies monoclonal030220 oncology & carcinogenesisMonoclonalbiology.proteinCancer researchMedicine030211 gastroenterology & hepatologyPharmacology (medical)Tumor necrosis factor alphaAnti-tumour necrosis factor alpha agentAntibodybusinessAlimentary Pharmacology & Therapeutics
researchProduct

Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications

2008

Azathioprine and 6-mercaptopurine represent important first-line immunosuppressive drugs in the treatment of inflammatory bowel disease. Owing to 45 years of clinical experience with thiopurines in inflammatory bowel disease, there currently exist strong data from numerous clinical trials and meta-analyses, which clearly document the therapeutic efficacy of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. However, the exact molecular mechanism of action of these drugs was insufficiently understood for a long time. During the last few years, important new insights into the intracellular effects of azathioprine have been gained and thiopurines have been identi…

Hepatologybusiness.industryGastroenterologyAzathioprineInflammatory Bowel Diseasesmedicine.diseaseBioinformaticsInflammatory bowel diseaseClinical trialAzathioprineImmunologyMolecular mechanismHumansMedicinebusinessImmunosuppressive Agentsmedicine.drugExpert Review of Gastroenterology & Hepatology
researchProduct

The frame-shift mutation of the NOD2/CARD15 gene is significantly increased in ulcerative colitis: An ∗IG-IBD study

2004

Hepatologybusiness.industryInflammatory Bowel DiseaseGastroenterologymedicine.diseaseUlcerative colitisFrameshift mutationCrohn DiseaseNOD2ImmunologymedicineCD susceptibilityColitisbusinessAllele frequencyGeneGastroenterology
researchProduct